Minimal residual disease in acute myeloid leukaemia

Best Practice and Research: Clinical Haematology

Volumn 15, Issue 1, 2002, Pages 119-135

  Liu Yin, J A ^a  

^a MANCHESTER ROYAL INFIRMARY   (United Kingdom)

Author keywords

AML; AML MTG8; CBFB MYHII; MRD; Multiparameter flow cytometry; Qualitative; Quantitative; Real time; RT PCR; WTI

Indexed keywords

ACUTE GRANULOCYTIC LEUKEMIA; ARTICLE; CANCER RECURRENCE; CHROMOSOME INVERSION; CHROMOSOME TRANSLOCATION 21; CHROMOSOME TRANSLOCATION 8; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; GENE FUSION; GENE TARGETING; GENETIC TRANSCRIPTION; HIGH RISK PATIENT; HUMAN; LEUKEMIA REMISSION; METHODOLOGY; MINIMAL RESIDUAL DISEASE; PATIENT MONITORING; PRIORITY JOURNAL; PROSPECTIVE STUDY; QUANTITATIVE ANALYSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SENSITIVITY AND SPECIFICITY; TREATMENT FAILURE; ACUTE DISEASE; GENE TRANSLOCATION; GENETICS; MYELOID LEUKEMIA; REVIEW; CANCER DIAGNOSIS; CHROMOSOME TRANSLOCATION; CYTOGENETICS; FLOW CYTOMETRY; FLUORESCENCE IN SITU HYBRIDIZATION; MONITORING; NUCLEIC ACID AMPLIFICATION; QUALITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION;

ONCOPROTEIN; RNA; MYOSIN HEAVY CHAIN; WT1 PROTEIN;

ACUTE DISEASE; HUMANS; LEUKEMIA, MYELOID; NEOPLASM, RESIDUAL; ONCOGENE PROTEINS, FUSION; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, NEOPLASM; TRANSLOCATION, GENETIC;

EID: 0036009614     PISSN: 15216926     EISSN: None     Source Type: Journal    
DOI: 10.1053/beha.2002.0188     Document Type: Article

References (81)

1. Minimal residual disease in acute leukaemia: Preclinical studies in a relevant rat model (BNML)
2. Detection of minimal residual disease in acute leukemia: Methodologic advances and clinical significance
3. Discrepant bone marrow aspirations in leukaemia
4. Non-homogeneous distribution of leukemia in the bone marrow during minimal residual disease
5. Cytogenetic studies and their clinical correlates in adults with acute leukemia
6. Evolution of karyotypes in acute nonlymphocytic leukemia
7. Cytogenetics for detection of minimal residual disease in acute myeloblastic leukemia
8. Detecting genetic changes in human tumour cells: Have scientists 'gone fishing?'
9. Detection of 16p deletions by FISH in patients with inv(16) or t(16;16) and acute myeloid leukemia (AML)
10. Application of fluorescence in situ hybridisation to detect residual leukemic cells with 9;22 and 15;17 translocations
11. Clonality analysis of hematopoietic cell lineages in acute myeloid leukemia and translocation (8;21): Only myeloid cells are part of the malignant clone
12. Prognostic value of metaphase-fluorescence in situ hybridisation in follow-up of patients with acute myeloid leukemia in remission
13. Detection of bcr-abl fusion in chronic myelogenous leukemia by in situ hybridisation
14. Analytical approaches to detection and characterisation of disease-linked chromosome aberrations
15. Monitoring of residual disease in chronic myelogenous leukemia: Methodological approaches and clinical aspects
16. Improved sensitivity of BCR-ABL detection: A triple-probe three-color fluorescence in situ hybridisation system
17. + malignant myeloblasts has implications for minimal residual disease in acute myeloid leukemia
18. Expression of unusual immunophenotype combinations in acute myelogenous leukemia
19. Immunological detection of blast cell subpopulations in acute myeloblastic leukemia at diagnosis: Implications for minimal residual disease studies
20. Prediction of relapse of paediatric acute myeloid leukemia by use of multidimensional flow cytometry
21. Immunophenotyping investigations of minimal residual disease is a useful approach for predicting relapse in acute myeloid leukemia patients
22. Level of minimal residual disease after consolidation therapy predicts outcome in acute myeloid leukemia
23. High frequency of immunophenotype changes in acute myeloid leukemia at relapse: Implications for residual disease detection
24. Detection of minimal residual disease in acute myeloid leukaemia: Methodologies, clinical and biological significance
25. Frequent detection of minimal residual disease by use of the polymerase chain reaction in long-term survivors after bone marrow transplantation for chronic myeloid leukemia
26. Polymerase chain reaction detection of the BCR-ABL fusion transcript after allogeneic marrow transplants for chronic myeloid leukemia: Results and implications in 346 patients
27. Competitive polymerase chain reaction to estimate the number of BCR-ABL transcripts in chronic myeloid leukemia patients after bone marrow transplantation
28. Monitoring of minimal residual disease by quantitative reverse transcriptase polymerase chain reaction for AML-MTG8 transcripts in AML-M2 with t(8;21)
29. Quantitative PCR techniques and applications
30. Detection and quantitation of the CBFB/MTHYII transcripts associated with the inv(16) in presentation and follow-up samples from patients with AML
31. Identification of breakpoints in t(8;21) AML and isolation of a fusion transcript with similarity to Drosophila segmentation gene runt
32. An AMLI/ETO fusion transcript is consistently detected by RNA-based polymerase chain reaction in acute myelogenous leukemia containing the (8;21)(q22;q22) translocation
33. Detection of DNA rearrangements in the AMLI and ETO loci and of an AMLI/ETO fusion mRNA in patients with t(8;21) acute myeloid leukaemia
34. (8;21) translocation in acute granulocytic leukaemia: Cytological, cytochemical and clinical features
35. The importance of diagnostic cytogenetics on outcome in AML: Analysis of 1612 patients entered into the MRC AML 10 trial
36. Persistence of the 8;21 translocation in patients with acute myeloid leukaemia type M2 in long-term remission
37. AMLI/ETO fusion mRNA can be detected in remission blood samples of all patients with t(8;21) acute myeloid leukemia after chemotherapy or autologous bone marrow transplantation
38. Detection of t(8;21) by reverse transcriptase polymerase chain reaction in patients in remission of acute myeloid leukaemia type M2 after chemotherapy or bone marrow transplantation
39. Persistence of the AML/ETO fusion transcript in patients treated with allogeneic bone marrow transplantation for t(8;21) leukemia
40. Use of polymerase chain reaction in the detection of AMLI/ETO fusion transcript in t(8;21)
41. Disappearance of AMLI-MTG8(ETO) fusion transcript in acute myeloid leukaemia patients with t(8;21) in long-term remission
42. Evaluation of minimal residual disease using RT-PCR in t(8;21) AML: A multicentre study on 50 patients
43. Evaluation of minimal residual disease using reverse-transcriptase polymerase chain reaction in t(8;21) acute myeloid leukemia: A multicentre study of 51 patients
44. Molecular quantitation of minimal residual disease in acute myeloid leukaemia with t(8;21) can identify patients in durable remission and predict clinical relapse
45. Comparison of nested competitive RT-PCR and real-time RT-PCR for the detection and quantitation of AML-MTG8 fusion transcripts in t(8;21) positive AML
46. Real-time RT-PCR for the detection and quantitation of AMLI-MTG8 fusion transcripts in t(8;21) positive AML patients
47. Quantitation of minimal residual disease in t(8;21) positive acute myelogenous leukemia patients using real-time quantitative RT-PCR
48. Association of an inversion of chromosome 16 with abnormal marrow eosinophils in acute myelomonocytic leukemia: A unique cytogenetic-clinico-pathological association
49. Fusion between transcription factor CBFβ/PEBP 2β and a myosin heavy chain in acute myeloid leukemia
50. Detection of fusion transcripts generated by the inversion 16 chromosome in acute myelogenous leukemia
51. Detection of minimal residual disease in acute myelomonocytic leukemia with abnormal marrow eosinophils by nested polymerase chain reaction with allele specific amplification
52. Detection of CBFB/MYHII transcripts in patients with inversion and other abnormalities of chromosome 16 at presentation and remission
53. Molecular pathogenesis of the chromosome 16 inversion in the M4EO subtype of acute myeloid leukemia
54. Detection of the chromosome 16 CBFB-MYHII fusion transcript in myelomonocytic leukemias
55. Frequency of CBFB/MYHII fusion transcripts in patients entered into the UK MRC AML trials
56. Acute myelomonocytic leukemia with abnormal eosinophils and inv(16) and t(16;16) has a favourable prognosis
57. Abnormalities of chromosome 16q in myeloid malignancy: 14 new cases and a review of the literature
58. Detection of CBFB/MYHII fusion transcript in patients with inv(16) acute myeloid leukaemia after allogeneic bone marrow or peripheral blood progenitor cell transplantation
59. Prognostic value of residual disease monitoring by polymerase chain reaction in patients with CBFB-MYHII positive acute myeloblastic leukaemia
60. Defining the 'absence' of the CBFB-MYHII fusion transcripts in patients with acute myeloid leukaemia and inversion of chromosome 16 to predict long-term complete remission: A call for definitions
61. Competitive CBFB-MYHII reverse-transcription polymerase chain reaction for quantitative assessment of minimal residual disease during post-remission therapy in acute myeloid leukemia with inversion (16): A pilot study
62. Quantification of CBFB/MYHII fusion transcripts by real-time RT-PCR in patients with inv(16) acute myeloid leukemia
63. Real-time quantitation of minimal residual disease in inv(16) positive acute myeloid leukemia can predict clinical relapse and identify patients in a curable state
64. Evaluation of minimal residual disease in inv(16) by qualitative and quantitative RT-PCR assays of CBFB-MYHII fusion transcripts
65. Prospective monitoring of minimal residual disease in acute myeloid leukemia with inv(16) by CBFB-MYHII RT-PCR: Implications for a monitoring schedule and for treatment decisions
66. Detection and quantification of CBFB/MYHII fusion transcripts in patients with inv(16) positive acute myeloblastic leukemia by real-time PCR
67. Monitoring of minimal residual leukaemia in patients with MLL-AF9 positive acute myeloid leukemia by RT-PCR
68. Monitoring of minimal residual disease in patients with MLL-AF6 - Positive acute myeloid leukaemia by reverse transcriptase polymerase chain reaction
69. Detection of minimal residual disease in a patient having acute myelogenous leukemia with t(16;21)(p11;q22) treated by allogeneic bone marrow transplantation
70. Loss of the DEK-CAN fusion transcript in a child with t(6;9) acute myeloid leukemia following chemotherapy and allogeneic bone marrow transplantation
71. Homozygous deletion in Wilm's tumours of a zinc-finger gene identified by chromosome jumping
72. Quantitative monitoring of the PRAME gene for the detection of minimal residual disease in leukaemia
73. Expression of the Wilm's tumour gene (WTI) in human leukemias
74. WTI as a new prognostic factor and new marker for the detection of minimal disease in acute leukemia
75. High levels of Wilm's tumour gene (WTI) mRNA in acute myeloid leukemias are associated with a worse long-term outcome
76. Long-term follow-up of minimal residual disease in leukemia patients by monitoring WTI (Wilm's tumour gene) expression levels
77. Detection of the WTI transcript by RT-PCR in complete remission has no prognostic relevance in de novo acute myeloid leukemia
78. Predictive and prognostic significance of quantitative analysis of WTI gene transcripts by RT-PCR in acute leukaemia
79. RT-PCR and RT-Q-PCR aimed at detection of the Wilm's tumour gene expression may serve as markers for malignant haematopoiesis and for minimal residual disease detection in acute leukaemia patients
80. Fluorescent 5′ exonuclease assay for the absolute quantification of Wilm's tumour gene (WTI) mRNA: Implications for monitoring human leukaemias
81. Incidence of AMLI/ETO fusion transcripts in patients entered into the MRC AML trials